Skip to main navigation

Skip Navigation

- Landos - Corp Menu

About Us
- Our Company
- Contact Us
Product Candidates
Science
Investors/Media
Careers
- Why Landos?
- Open Positions

Identifying novel pathways at the interface of immunity and metabolism

Press Releases

Year

11/21/23

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

11/9/23

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

10/23/23

Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

9/19/23

Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress

9/14/23

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

8/9/23

Landos Biopharma Provides Business Update & Reports Second Quarter 2023 Results

5/31/23

Landos Biopharma to Present at the 2023 Jefferies Healthcare Conference

5/30/23

Landos Biopharma Expands Board of Directors with Appointment of Alka Batycky, Ph.D.

5/25/23

Landos Biopharma Announces 1-for-10 Reverse Stock Split

5/12/23

Landos Biopharma Provides Business Update and Reports First Quarter 2023 Results

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 10 of 15

Investors/Media

Investor Relations

Investor/Media Home
Press Releases
Events & Presentations
Analyst Coverage
Stock Information
SEC Filings
Corporate Governance
Investors/Media FAQs

- Landos - Investor Tools

Print Page
RSS Feeds
Email Alerts

Landos Biopharma, Inc.
PO Box 11239
Blacksburg, VA 24062

info@landosbiopharma.com
(540) 218-2232

- Landos - Footer Menu

Site Map
Terms of Use
Privacy Policy

©2023 Landos Biopharma All Rights Reserved.